CervoMed Inc.
$ 3.98
-0.25%
17 Apr - close price
- Market Cap 36,849,700 USD
- Current Price $ 3.98
- High / Low $ 4.18 / 3.98
- Stock P/E N/A
- Book Value 1.97
- EPS -2.98
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.54 %
- ROE -0.94 %
- 52 Week High 11.79
- 52 Week Low 3.51
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$22.14
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-16 | 2025-11-07 | 2025-08-08 | 2025-06-13 | 2025-03-31 | 2024-11-11 | 2024-08-09 | 2024-05-14 | 2024-03-29 | 2023-11-13 | 2023-08-08 | 2023-05-15 |
| Reported EPS | -0.88 | -0.84 | -0.7 | -0.56 | -0.8 | -0.5462 | -0.27 | -0.41 | -0.38 | -0.7 | -1.5537 | -2.01 |
| Estimated EPS | -0.7017 | -0.46 | -0.68 | -0.6233 | -0.6343 | -0.41 | -0.31 | -0.39 | -0.29 | -0.95 | -2.9 | -1.91 |
| Surprise | -0.1783 | -0.38 | -0.02 | 0.0633 | -0.1657 | -0.1362 | 0.04 | -0.02 | -0.09 | 0.25 | 1.3463 | -0.1 |
| Surprise Percentage | -25.4097% | -82.6087% | -2.9412% | 10.1556% | -26.1233% | -33.2195% | 12.9032% | -5.1282% | -31.0345% | 26.3158% | 46.4241% | -5.2356% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.9 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRVO
2026-04-15 15:10:20
This article focuses on the operating cash flow per share of CervoMed Inc. (FWB:DP8), as presented on TradingView. It indicates that the market for this stock was closed at the time of publication and provides no specific financial figures, serving primarily as a placeholder or introductory page for the company's financial data on the platform.
2026-04-11 17:40:28
CervoMed Inc (CRVO.O) is currently classified as overvalued based on its forward PS ratio of 59.70 compared to its five-year average of -5.71. The fair price for CRVO.O is estimated to be between $0.56 and $2.79, making its current price of $3.83 USD approximately 37.08% overvalued. Key metrics like P/B ratio and Forward Free Cash Flow (FCF) yield also indicate potential overvaluation relative to historical averages.
2026-04-10 02:10:12
This article provides a technical analysis and stock price forecast for CervoMed Inc (CRVO), concluding with a "Strong Sell" consensus. The analysis is based on various technical indicators, including moving averages, RSI, and MACD, highlighting that CRVO is trading below its key moving averages and has mostly sell signals from its oscillators. Key support and resistance levels are identified, along with information on its current RSI and MACD status.
2026-04-09 19:40:23
This article provides an overview of the financial information available for CRVO.O, including sections for revenue breakdown, profitability and margins, and competitor comparison. It also lists various financial statements and key indicators that users can explore, such as income statements, balance sheets, and cash flow. The page serves as a financial hub for analyzing CRVO.O's performance.
2026-04-09 11:40:23
CervoMed Inc. is preparing to launch a Phase 3 clinical trial later this year focusing on dementia with Lewy bodies (DLB). This decision follows CEO Dr. John Alam's participation in a panel discussing the role of biomarkers in DLB diagnosis and treatment. Earlier analyses from Phase 2B trials indicated that neflamapimod, a treatment developed by CervoMed, was more effective in DLB patients with less Alzheimer co-pathology.
2026-04-08 12:39:03
D. Boral Capital has reaffirmed its "Buy" rating for CervoMed (CRVO) with an unchanged price target of $31, signaling continued confidence in the company's market position and growth potential. This decision follows consistent analyst support for CRVO, a clinical-stage biotechnology company focusing on treatments for age-related neurologic disorders. Wall Street analysts collectively project an average one-year price target of $22.14 for CervoMed, representing a significant upside from its current price.
